周学敏,郭莉青,王燕庆,柴婵娟,吕慧,朱国斌

• 1:山西医科大学第二医院心内科

摘要(Abstract)：

目的对比分析急性冠状动脉综合征(ACS)合并慢性阻塞性肺病(COPD)患者使用替格瑞洛与氯吡格雷的临床疗效及安全性。方法纳入2013年1月1日至2014年10月1日入住山西医科大学第二医院诊断为ACS合并COPD的患者73例,随机分为替格瑞洛组(38例)和氯吡格雷组(35例)。替格瑞洛组使用替格瑞洛联合阿司匹林规律抗血小板聚集治疗。氯吡格雷组使用氯吡格雷联合阿司匹林抗血小板聚集治疗。随访1年,观察两组患者主要不良心脑血管事件(MACCE,包括心原性死亡、再发心肌梗死、缺血性脑卒中)以及全因死亡事件。结果两组患者心原性死亡、缺血性脑卒中、再发心肌梗死、全因死亡、小出血、轻微出血、停用药物(替格瑞洛或氯吡格雷)等比较,差异均无统计学意义(均P>0.05);替格瑞洛组患者MACCE发生率(5.3%比25.7%,P=0.04)显著低于氯吡格雷组,差异有统计学意义;而呼吸困难发生率(26.3%比5.7%,P=0.04)显著高于氯吡格雷组,差异亦有统计学意义,但除替格瑞洛组1例患者因呼吸困难而停药后症状自行消失,其余均为一过性轻度呼吸困难。结论阿司匹林联合替格瑞洛可显著减少ACS合并COPD患者的MACCE发生率,而不增加出血风险;虽然增加了呼吸困难的发生,但绝大部分为一过性或轻-中度呼吸困难,并未影响心肺功能。

关键词(KeyWords)： 急性冠状动脉综合征;慢性阻塞性肺疾病;替格瑞洛;氯吡格雷

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 周学敏,郭莉青,王燕庆,柴婵娟,吕慧,朱国斌

参考文献(References)：

• [1]Sidney S,Sorel M,Quesenberry CP Jr,et al.COPD and incident cardiovascular disease hospitalizations and mortality:Kaiser Permanente Medical Care Program.Chest,2005,128(4):2068-2075.
• [2]Quint JK,Herrett E,Bhaskaran K,et al.Effect ofβblockers on mortality after myocardial infarction in adults with COPD:population based cohort study of UK electronic healthcare records.BMJ,2013,347:f6650.
• [3]Andell P,Koul S,Martinsson A,et al.Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction.Open Heart,2014,1(1):e000002.
• [4]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361(11):1045-1057.
• [5]Gensini GG.A more meaningful scoring system for determining the severity of coronary heart disease.Am J Cardiol,1983,51(3):606.
• [6]颜红兵,邵春丽,霍勇.要重视替格瑞洛相关的呼吸困难.中国介入心脏病学杂志,2015,23(01):2-4.
• [7]高润霖.替格瑞洛——ACS患者的更好选择.医学研究杂志,2011,40(1):1-2.
• [8]Amsterdam EA,Wenger NK,Brindis RG,et al.2014 AHA/ACC Guideline for the management of patients with Non-ST-elevation acute coronary syndromes:a report of the American College of Cardiology/American Heart Association task force on practice guidelines.J Am Coll Cardiol,2014,64(24):e139-e228.
• [9]Roffi M,Patrono C,Collet JP,,et al.2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology(ESC).Eur Heart J,2016,37(3):267-315.
• [10]中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本).中华危重症医学杂志(电子版),2012,5(3):169-180.
• [11]金枚.急性ST段抬高型心肌梗死诊断和治疗指南.中华心血管病杂志,2010,38(8):675-690.
• [12]Salisbury AC,Reid KJ,Spertus JA.Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes.Am J Cardiol,2007,99(5):636-641.
• [13]Bursi F,Vassallo R,Weston SA,et al.Chronic obstructive pulmonary disease after myocardial infarction in the community.Am Heart J,2010,160(1):95-101.
• [14]Campo G,Guastaroba P,Marzocchi A,et al.Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention.Chest,2013,144(3):750-757.
• [15]Montone RA,Hoole SP,West NE.Prehospital ticagrelor in ST-segment elevation myocardial infarction.N Engl J Med,2014,371(24):2338-2339.
• [16]Lindholm D,Varenhorst C,Cannon CP,et al.Ticagrelor vs.clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization:results from the PLATO trial.Eur Heart J,2014,35(31):2083-2093.
• [17]Kotsia A,Brilakis ES,Held C,et al.Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome:Insights from the PLATelet inhibition and patient Outcomes(PLATO)trial.Am Heart J,2014,168(1):68-75.
• [18]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361(11):1045-1057.
• [19]Parodi G,Storey RF.Dyspnoea management in acute coronary syndrome patients treated with ticagrelor.Eur Heart J Acute Cardiovasc Care,2015,4(6):555-560.
• [20]Storey RF,Becker RC,Harrington RA,et al.Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.Eur Heart J,2011,32(23):2945-2953.
• [21]Storey RF,Becker RC,Harrington RA,et al.Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel(from the Platelet Inhibition and Patient Outcomes[PLATO]pulmonary function substudy).Am J Cardiol,2011,108(11):1542-1546.
• [22]Storey RF,Bliden KP,Patil SB,et al.Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor,clopidogrel,or placebo in the ONSET/OFFSET study.J Am Coll Cardiol,2010,56(3):185-193.